Conférences  >  Médecine & Soins de Santé  >  Hématologie

event lab. GmbH

Die immer komplexer werdenden Patientenverläufe erfordern intensive Recherchen und kollegialen Austausch. Einige ausgewählte Fragen werden Schwerpunkt der Fortbildung sein, welche die spezielle Fallvorstellung und einen dazu komplementären Übersichtsvortrag beinhaltet.

Hämatologie, Weiterbildung

Binaytara Foundation

This CME-accredited activity Cellular Therapy in Hematology and Oncology: Expert Guidance for Clinical Practice features leading experts in hematologic malignancies and cellular therapies who will provide a comprehensive overview of current and emerging strategies for the management of lymphoma, myeloma, acute leukemias, and solid tumors with a focus in the use of cellular therapies. The goal of this activity is to improve the knowledge and competence of learners to apply practice-changing clinical data and expert recommendations to optimize clinical outcomes for patients with hematologic malignancies and to describe potential future applications of cellular therapy in solid tumors. The activity will use a mix of didactic lectures and case-based discussions to highlight areas of debate between cellular therapy and non-cellular therapy in the treatment of these diseases. Expert faculty will aim to place the role of different therapeutic agents in a clinical context and discuss how to utilize these therapeutic options to effectively contribute to patient care. This conference is designed to provide physicians, physician assistants, nurse practitioners, pharmacists, nurses, and other healthcare professionals with the latest updates in the field. It will highlight a multidisciplinary approach and the integration of new advances in patient-centered care.

Tél.: [425-616-0572];     Email.: cme@binayfoundation.org

Cellular Therapy, Oncology, Hematology, Lymphoma, Myeloma, Acute Leukemia

Cancérologie,    Formation médicale continue (FMC)

Binaytara Foundation

This CME-accredited activity, Park City Lymphoma Myeloma Conference, features leading experts in hematologic malignancies who will provide a comprehensive overview of current and emerging strategies for the management of multiple myeloma, lymphoma, and Waldenström Macroglobulinemia. This activity aims to improve learners' knowledge and competence to apply practice-changing clinical data and expert recommendations to optimize clinical outcomes for patients with hematologic malignancies. The program features in-depth discussion and analysis of the latest scientific findings and practice-changing advances in newly diagnosed and relapsed multiple myeloma and lymphomas with a focus on emerging immunotherapies, including but not limited to CAR-T therapy and T-cell redirecting bispecific antibodies. Expert faculty will aim to place the role of different therapeutic agents in clinical contexts and discuss how to utilize these therapeutic options to effectively contribute to patient care.

Tél.: [425-616-0572];     Email.: cme@binayfoundation.org

Oncology, Hematology, Lymphoma, Myeloma, Waldenström Macroglobulinemia

Formation médicale continue (FMC),    Cancérologie

Binaytara Foundation

This CME-accredited activity, the 2024 Annual Summit on Hematologic Cancers, is a national meeting featuring leading experts in hematologic malignancies who will provide a comprehensive overview of current and emerging strategies for the management of acute myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, myeloproliferative neoplasms, multiple myeloma, and lymphoma. The goal of this activity is to improve the knowledge and competence of learners to apply practice-changing clinical data and expert recommendations to optimize clinical outcomes for patients with hematologic malignancies. The program features in-depth discussion and analysis of the latest scientific findings and practice-changing advances along with case-based discussion in the field of hematologic malignancies. Expert faculty will aim to place the role of different therapeutic agents in a clinical context and discuss how to utilize these therapeutic options to effectively contribute to patient care.

Tél.: [425-616-0572];     Email.: cme@binayfoundation.org

Hematology, Oncology, CME, Cancer

CME Congresses

The COSTEM Congress is a platform for our community to interact with each other and to share our scientific research, clinical experience, and on-going developments in our field. COSTEM encourages active participation in debate discussions and challenges global experts to promote their positions on a wide range of burning issues – providing clinicians the opportunity to share, express and compare experiences in order to establish and advance effective and reliable patient treatments. COSTEM 2024 will continue to push the envelope and be a progressive, compelling and informative congress, where the most compelling and controversial topics facing clinicians in our field are presented in a fascinating and exciting debate forum.

Event Secretariat;     Email.: costem@cme-congresses.com

Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, Myeloproliferative Neoplasms, Lymphoma and Myeloma, Non-malignancies, Pediatrics, Autoimmune Diseases, Cell Therapy, cytotoxic T lymphocytes

Medizinisches Zentrallabor – Abteilung Transfusionsmedizin und Klinische Hämostaseologie, Klinik für Hämatologie, Zelltherapie und Hämostaseologie Bereich Hämostaseologie, MVZ Labor Dr. Reising-Ackermann und Kollegen

event lab. GmbH;     Tél.: [0341 30 88 84 62];     Email.: asauerland@eventlab.org

Médecine vasculaire, Angéiologie,    Cancérologie

Verein fuer Leukaemieforschung und -Therapie e.V. Muenster together with Klinikum Großhadern, Munich,Germany

The symposium is taking place again in Munich, Germany, in-person from Sunday, March 16 until Wednesday, March 19, 2025. Additionally to the XI Main Sessions two free contributions sessions MS V (Poster session) and MS IX (Best of Free Contributions Session) will additionally deliver the possibility to all those who want to present their own research data in form of a free contribution and discuss their findings with the worldwide most renowned scientists and researchers in the field of acute leukemias. We therefore encourage all who are interested in actively participating in ISALXIX with a free contribution to submit their abstract(s). All accepted abstracts will be part of the open access ISALXIX supplement published in ANNALS OF HEMATOLOGY and in the Poster Viewing and Discussion Session (MSV). Abstract Submission Deadline: October 31, 2024.

Organizing Office Beate Buske-Kosel;     Tél.: [+49 160 615 1531];     Email.: info@acute-leukemias.de

MS I: Biology of Acute Leukemias MS II: Biology in Acute Leukemias MS III: Genetic and Molecular Characterization of AML: Novel Markers for Diagnosis and Prognosis MS IV: Novel Approaches and Targeted Therapies in AML MS VI: Risk adapted Therapy of AML MS VII: Biology and Treatment of APL MS VIII: MRD in Acute Leukemias: Methods and Clinical Applications MS X: Immunotherapy for Acute Leukemias MS XI: ALL: Biology and Treatment Strategies